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West Nile virus (WNV) is a neurotropic flavivirus transmitted by the bite of mosquitoes that causes meningitis and encephalitis
in humans, horses, and birds. Several studies have highlighted that flavivirus infection is highly dependent on cellular lipids for
virus replication and infectious particle biogenesis. The first steps of lipid synthesis involve the carboxylation of acetyl coenzyme
A (acetyl-CoA) to malonyl-CoA that is catalyzed by the acetyl-CoA carboxylase (ACC). This makes ACC a key enzyme of lipid
synthesis that is currently being evaluated as a therapeutic target for different disorders, including cancers, obesity, diabetes, and
viral infections. We have analyzed the effect of the ACC inhibitor 5-(tetradecyloxy)-2-furoic acid (TOFA) on infection byWNV.
Lipidomic analysis of TOFA-treated cells confirmed that this drug reduced the cellular content of multiple lipids, including
those directly implicated in the flavivirus life cycle (glycerophospholipids, sphingolipids, and cholesterol). Treatment with
TOFA significantly inhibited the multiplication ofWNV in a dose-dependent manner. Further analysis of the antiviral effect of
this drug showed that the inhibitory effect was related to a reduction of viral replication. Furthermore, treatment with another
ACC inhibitor, 3,3,14,14-tetramethylhexadecanedioic acid (MEDICA 16), also inhibitedWNV infection. Interestingly, TOFA
andMEDICA 16 also reduced the multiplication of Usutu virus (USUV), aWNV-related flavivirus. These results point to the
ACC as a druggable cellular target suitable for antiviral development againstWNV and other flaviviruses.
West Nile virus (WNV) is a mosquito-borne neurotropic fla-vivirus responsible for recurrent outbreaks of meningitis
and encephalitis affecting humans, horses, and birds in Africa,
Europe, Asia, Oceania, and America (1). A great effort has been
devoted in the past several years to decipher themolecular biology
of WNV and its interaction with the host immune system (2, 3).
Nevertheless, no licensed vaccine or therapy for human use
against this pathogen is yet available.
The flavivirus life cycle (including that of WNV) is intimately
associated with host cell lipids. The replication of the viral
genomic RNA and flavivirus nascent virion assembly take place in
modified membranes from the endoplasmic reticulum (4–7). To
build an adequate microenvironment to support viral replication
and particle biogenesis, flaviviruses rearrange host cell lipid me-
tabolism by promoting the synthesis and accumulation of specific
cellular lipids (i.e., fatty acids, glycerophospholipids [GPLs], sph-
ingolipids [SLs], and cholesterol) (8–15). Thismakes the pharma-
cological manipulation of cellular lipids an attractive antiviral
strategy against WNV and related flaviviruses (13, 14, 16, 17).
The first steps of lipid biogenesis involve the synthesis and
elongation of fatty acids, which provide the building blocks for the
synthesis of more-complex lipids. Hence, fatty acid synthesis and
elongation have become key targets for antiviral therapy (13, 18,
19). Regarding the flaviviruses, the pharmacological blockage of
the fatty acid synthase FASN (which catalyzes the synthesis of
palmitate from acetyl coenzyme A [acetyl-CoA] and malonyl-
CoA into long-chain saturated fatty acids) reduced the viral rep-
lication (11, 13). The enzyme preceding FASN in the fatty acid
biosynthetic route is the acetyl-CoA carboxylase (ACC), which
catalyzes the carboxylation of acetyl-CoA tomalonyl-CoA.Due to
its rate-limiting role in fatty acid synthesis, ACC is currently a
target of increasing interest within the pharmacological industry
(20, 21). However, to our knowledge, the involvement of ACC in
the replication of WNV, or other related flaviviruses, has not yet
been evaluated.
In this work, we have shown that ACC inhibitors alter the
cellular lipid composition and reduce the levels ofWNV infection
in cultured cells. Furthermore, infection by Usutu virus (USUV; a
related emerging flavivirus [22]) was also inhibited by the drugs
used. Our results point to ACC as a potential druggable antiviral
target against WNV and related flaviviruses.
MATERIALS AND METHODS
Cells, viruses, infections, and virus titrations. All infectious virus ma-
nipulations were performed in biosafety level 3 (BSL-3) facilities. Vero,
HeLa, and Neuro2a (N2a) cell lines were cultured as described previously
(10, 23). Cells were incubated with the corresponding virus, WNV strain
NY99orUSUV strain SAAR-1776 (24), for 1 h at 37°C; viral inoculumwas
removed; and infected cells were incubated in culturemedium containing
1% fetal bovine serum (time that was considered 1 h postinfection [p.i.]).
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Viral titer was determined 24 h p.i. by plaque assay in semisolid agarose
mediumusingVero cells (25). Themultiplicity of infection (MOI) used in
each experiment was expressed as PFU per cell and is indicated in the
corresponding figure legend.
Drug treatments. 5-(Tetradecyloxy)-2-furoic acid (TOFA) and
3,3,14,14-tetramethylhexadecanedioic acid (MEDICA 16) were from
Sigma (St. Louis, MO). Control cells were treated in parallel with the
same amount of drug vehicle (dimethyl sulfoxide [DMSO]). Unless
otherwise specified, drugs were added after the first hour of infection,
when viral inoculum was replaced by medium containing 1% fetal
bovine serum. Drug toxicity was examined by measuring the cellular
ATP content with the CellTiter-Glo luminescent cell viability assay
(Promega, Madison, WI).
Microscopy. Antibodies and procedures used for immunofluores-
cence and confocalmicroscopy, as well as sample processing for transmis-
sion electron microscopy, have been described previously (11). The anal-
ysis of fluorescence intensity was performed using ImageJ software (http:
//imagej.nih.gov/ij/).
Quantitative RT-PCR.Viral RNAwas extracted from the supernatant
of infected cultures with the Speedtools RNA virus extraction kit (Bioto-
ols, Madrid, Spain). For quantification of cell-associated viral RNA, su-
pernatants from infected cells were removed, cell monolayers were sub-
jected to three freeze-thaw cycles, and RNA was extracted as described
above. The amount of viral RNAwas determined by real-time fluorogenic
reverse transcriptase PCR (RT-PCR) as reported previously (26). The for-
ward primer 5=-CAGACCACGCTACGGCG-3=, the reverse primer 5=-C
TAGGGCCGCGTGGG-3=, and the probe 5=-FAM (6-carboxyfluores-
cein)-TCTGCGGAGAGTGCAGTCTGCGAT-3=-BHQ-1 (black hole
quencher 1) were used. Quantification was performed using the High
Scriptools-Quantimix Easy Probes kit (Biotools) and Rotor-Gene RG-
3000 equipment (Corbett Research). Genomic equivalents to PFU per
milliliter were calculated by comparison with 10-fold serial dilutions of
viral RNA extracted from previously titrated samples (27).
Lipid analysis. Vero cells were treated with 10 g/ml TOFA or with
DMSO and infected or not with WNV at a high MOI (50 PFU/cell) to
ensure that all cells were initially infected. Cells were detached from the
flasks and resuspended in phosphate-buffered saline (PBS) at 24 h p.i.
(10). Infections were performed in serum-free medium to avoid possible
biases introduced by lipids present in the serum. The number of cells in
each sample was determined, and aliquots containing 106 cells were sub-
jected to lipid extractions. Procedures for lipid extractions, identification,
and quantification by mass spectrometry have been previously described
(10, 28, 29). Annotation of lipid species followed the recommendations
indicated in reference 30. Glycerophospholipids, diacylglycerol (DAG),
triacylglycerol (TAG), and cholesteryl esters (CHOL) were annotated as
“lipid subclass” followed by “total fatty acyl chain length:total number of
unsaturated bonds” (e.g., PC 36:2). Plasmalogens were annotated as de-
scribed above, except that “p” was added. Lysophospholipids were anno-
tated as described above except that “lyso” was added. Sphingolipids were
annotated as “lipid subclass” followed by “total fatty acyl chain length:
total number of unsaturated bonds” (e.g., CER24:1). If the sphingoid base
residue was dihydrosphingosine, the lipid class contained a “dh” prefix.
For ceramide derivatives containing sugar moieties, the lipid class con-
tained a “hex” prefix to denote monohexosylceramides (glucosylcer-
amides and galactosylceramides) or a “lac” prefix for lactosylceramides.
Data analysis. Data are presented as means  standard deviations
(SDs). Analysis of variance (ANOVA) and Student’s t test were performed
with SPSS 15 (SPSS Inc., Chicago, IL). Bonferroni’s correction was ap-
plied for multiple comparisons. Statistically significant differences were
considered at a P value of0.05.
RESULTS
Effect of inhibition of ACC on cellular lipid content.TOFA is an
inhibitor of ACC that has been used to evaluate the involvement of
this enzyme in infections by a variety of viruses (18, 31–34). To
determine its effect on the cellular lipid content, Vero cells were
treated with TOFA for 24 h and the lipid content was analyzed by
mass spectrometry and compared to that of control cells treated in
parallel with the same amount of drug solvent (Fig. 1). These
experiments were performed in serum-freemedium to avoid pos-
sible interference of serum lipids in the analysis. Eighteen lipid
classes (3 neutral lipids [NLs], 10 glycerophospholipids [GPLs],
and 5 sphingolipids [SLs]) were included in the analysis (Fig. 1A).
A significant decrease in the amount of NLs (triacyclglycerol
[TAG], diacylglycerol [DAG], and cholesteryl esters [CHOL])was
observed in TOFA-treated cells (Fig. 1A). Among SLs, ceramide
(CER), monohexosylceramide (hexCER), lactosylceramide (lac-
CER), sphingomyelin (SM), and dihydroSM (dhSM) were ana-
lyzed. The amount of CER and its derivatives containing sugar
moieties (hexCER and lacCER) was significantly reduced in
TOFA-treated cells. In contrast, the content of SM and dhSMwas
not significantly reduced by treatment with TOFA (Fig. 1A). To
evaluate the effect of TOFA on the cellular GPLs, we analyzed the
content of phosphatidylcholine (PC), 1-alkenyl-2-acyl-glycero-3-
phosphocholine (referred to as plasmalogen-PC [p-PC; plasme-
nylcholine]), 1-acyl-glycero-3-phosphocholine (lyso-PC), lyso-
plasmenylcholine (lyso-p-PC), phosphatidylethanolamine (PE),
1-alkenyl-2-acyl-glycero-3-phosphoethanolamine(p-PE),1-acyl-
glycero-3-phosphoethanolamine (lyso-PE), lyso-p-PE, phospha-
tidylserine (PS), and 1-acyl-glycero-3-phosphoserine (lyso-PS). A
significant decrease in the amount of PC, p-PC, PE, p-PE, and PS
was noted in TOFA-treated cells, whereas no significant change in
the lysolipids analyzed (lyso-PC, lyso-p-PC, lyso-PE, lyso-p-PE,
and lyso-PS) was induced by treatment with TOFA. The lack of
reduction in the amount of lysolipids can be explained because
lysolipids are produced by the action of phospholipases (35)
rather than by a biosynthetic process. Among the 18 lipid classes
analyzed, a total of 208 different molecular species could be iden-
tified (Fig. 1B to H). From these species, 89 remained unaltered in
TOFA-treated cells (42.8%) and a significant increase was ob-
served in only three of the identified species (1.4%) that corre-
sponded to lysolipids (Fig. 1H). Such an increase could likely cor-
respond to a stress response including the activation of
phospholipases (35). On the other hand, on 116 lipid species
(55.8%) a significant reduction was noted, confirming that inhi-
bition of ACC using TOFA has a major impact on lipid synthesis,
reducing the content of a wide variety of cellular lipids.
TOFA inhibits infection byWNV and USUV.Vero cells were
infected with WNV, and different concentrations of TOFA were
added 1 h p.i. to avoid possible interference of the drug with virus
entry. TOFA inhibited WNV multiplication in a dose-dependent
manner (Fig. 2A and B). Both the production of infectious parti-
cles (Fig. 2A) and the release of genome-containing particles to the
culture medium (Fig. 2B) were significantly reduced by TOFA.
The toxicity of the drug was analyzed in parallel by determination
of the cellular ATP content (Fig. 2C), confirming that the concen-
trations of TOFA tested inhibited WNV infection, exerting small
effects on cell viability. A time course analysis of the production of
infectious virus revealed that TOFA inhibited the multiplication
ofWNV also at time points as early as 12 h p.i. (Fig. 2D). Next, the
effect of TOFA onWNV infection in other cell lines was tested. An
inhibition similar to that observed on Vero cells (Fig. 2A and B)
was noted in TOFA-treated HeLa cells (Fig. 2E and F). Consider-
ing that WNV is a neurotropic virus, the effect of TOFA was also
assayed in the neuroblastoma cell line N2a. TOFA also inhibited
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the infection of WNV in N2a cells, showing also a minor impact
on cell viability (Fig. 2G and H). When N2a cells were used to
address the effect of TOFAaddition to infected cultures at 1, 4, and
8 h p.i., a significant inhibition ofWNV infection was observed in
all cases (Fig. 2I), indicating that treatment with TOFA impaired
WNV infection after virus entry. Even more, TOFA also signifi-
cantly reduced the production of USUV, a related flavivirus, in
Vero, HeLa, and N2a cells (Fig. 2J). These results suggest that the
FIG1 Alterationsof cellular lipid contentupon inhibitionofACCusingTOFA. (A)Relative amounts of different classes ofNLs, SLs, andGPLs inVero cells treatedwith
10 g/ml TOFA or not treated (DMSO) determined by mass spectrometry at 24 h after drug addition. The experiments were performed in serum-free medium.
Statistically significant differences are indicated: *, P 0.05; **, P 0.005. (B toH) Relative amounts of different lipidmolecular species (NLs [B], SLs [C], PC [D], PE
[E], PS [F], plasmalogens [G], and lysophospholipids [H]) in cells treatedwith TOFA as in panel A. Black bars denotemolecular species significantly altered (P 0.05)
relative to control cells. Gray bars denotemolecular species not significantly changed relative to untreated cells. Bars corresponding to untreated cells have been omitted
from the figure for clarity. Dashed lines, mean value for each lipid in untreated cells. Data are presented as means SDs (three replicates).
Acetyl-CoA Carboxylase Inhibitors and WNV
January 2016 Volume 60 Number 1 aac.asm.org 309Antimicrobial Agents and Chemotherapy
 o
n
 June 29, 2016 by Red de Bibliotecas del CSIC
http://aac.asm
.org/
D
ow
nloaded from
 
inhibition of ACC can be also effective against other related flavi-
viruses.
TOFA inhibits the replicationofWNVgenome.The infection
with WNV induces marked changes in the intracellular mem-
brane architecture to create an appropriatemicroenvironment for
viral replication (7, 11). Hence, we analyzed the effect of TOFA on
Vero cells infected with WNV by means of transmission electron
microscopy (Fig. 3A). Mock-infected cells treated with TOFA or
not treated exhibited normal cellular architecture (Fig. 3A, upper
panels). In contrast, control infected cells not treated with TOFA
exhibited characteristic infection-associated ultrastructural alter-
ations, such as convoluted membranes (CM), vesicle packets
(VPs), and electron-dense virions (Vi) (Fig. 3A, lower left panel).
In infected cells treated with TOFA, Vi could be recognized but
properly arranged CM or VPs, such as those observed in control
cells, could not be detected. Instead, disordered VP-like materials
and small cumuli of membranous materials resembling CM were
observed (Fig. 3A, lower right panel). Since the replication of the
flavivirus genome takes place in the VP (4, 36), our observations
could indicate that the alteration of cellular lipids induced by
TOFA impaired the development ofWNV replication complexes.
To support this hypothesis, the amount of double-stranded RNA
(dsRNA) intermediates (a well-characterized marker of flavivirus
replication complex [4, 7]) was analyzed by immunofluorescence
in infected cells treated or not treated with TOFA (Fig. 3B). As
expected, no dsRNA was detected in uninfected cells, treated or
not treated with TOFA (Fig. 3B, upper panels). In contrast,
dsRNA was observed in both control and TOFA-treated cells in-
FIG 2 TOFA inhibitsWNV andUSUVmultiplication. (A) Reduction ofWNV infectious particle production in Vero cells treated with different concentrations
of TOFA. Cells were infected with WNV (MOI of 0.5 PFU/cell), and virus yield in culture supernatant was determined by plaque assay at 24 h p.i. (B)
Quantification by quantitative RT-PCR of genome-containing particles in culture supernatant of Vero cells infected as in panel A. (C) Evaluation of the toxicity
of TOFA on Vero cells by determination of cellular ATP content 24 h posttreatment. (D) Time course analysis of virus production in TOFA-treated cells. Vero
cells were infected withWNV (MOI of 1 PFU/cell) and treated with 10 g/ml TOFA. The amount of infectious virus in the supernatant of infected cultures was
determined by plaque assay at different times p.i. (E) Reduction of WNV infectious particle production (24 h p.i.) in HeLa cells infected (MOI of 0.5 PFU/cell)
and treatedwith TOFA. (F) Evaluation of the toxicity of TOFAonHeLa cells 24 h posttreatment. (G) Reduction ofWNV infectious particle production (24 h p.i.)
inN2a cells infected (MOIof 0.5 PFU/cell) and treatedwithTOFA. (H)Evaluation of the toxicity of TOFAonN2a cells 24 hposttreatment. (I) Inhibition ofWNV
multiplication in N2a cells by adding TOFA at different times p.i. N2a cells were infected with WNV (MOI of 0.5 PFU/cell), and 10 g/ml TOFA was added at
the indicated time points. Virus yield was determined by plaque assay at 24 h p.i. (J) Inhibition of USUV infection in different cell lines using TOFA. Vero, HeLa,
and N2a cells were infected with USUV (MOI of 0.5 PFU/cell) and treated with TOFA. Virus yield was determined by plaque assay at 24 h p.i. Data are presented
as means SDs (three replicates). Statistically significant differences are indicated: *, P 0.05; **, P 0.005.
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fected with WNV. However, the intensity of the dsRNA fluores-
cence was lower in infected cells treated with TOFA than in con-
trol infected cells (Fig. 3B, lower panels). The quantification of this
signal confirmed a statistically significant reduction in the cellular
content of dsRNA intermediates in TOFA-treated cells (Fig. 3C).
Furthermore, the analysis by quantitative RT-PCR revealed that
treatment with TOFA induced a statistically significant dose-de-
pendent reduction in the amount of cell-associated viral RNA
FIG 3 Effect of TOFA on replication of WNV. (A) Intracellular membrane rearrangements in WNV-infected Vero cells observed by transmission electron
microscopy 24 h p.i. Upper panels show representative images of uninfected cells untreated (left) or treated with 10 g/ml TOFA (right). Lower panels display
representative images of infected cells (MOI, 10 PFU/cell) untreated (left) or treated with TOFA (right). VP, vesicle packet; Vi, virion; CM, convoluted
membranes; ER, endoplasmic reticulum. Bars, 200 nm. (B) Visualization of intracellular dsRNA accumulation in cells infected with WNV (MOI, 10 PFU/cell)
and treated with 10 g/ml TOFA at 24 h p.i. Cells were fixed and processed for immunofluorescence using monoclonal antibody to dsRNA J2 and a secondary
antibody coupled to Alexa Fluor 488 (green). Nuclei were stained with ToPro-3 (blue). Mock-infected cells processed in parallel are also included as a control.
Bars, 10 m. (C) Quantification of the fluorescence intensity of dsRNA in cells infected and treated with TOFA as shown in panel B. (D) Amount of
cell-associated viral RNA in cell cultures infected withWNV (MOI of 0.5 PFU/cell) and treated with TOFA determined by quantitative RT-PCR at 24 h p.i. Data
are presented as means SDs (three replicates). Statistically significant differences are indicated: *, P 0.05; **, P 0.005.
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(Fig. 3D). Taken together, these results suggest that the alteration
of cellular lipid content induced by TOFA impairs WNV replica-
tion complex assembly and hence viral replication.
TOFA reduces the lipid content of WNV-infected cells. The
amount of lipids in WNV-infected cells was analyzed by mass
spectrometry (Fig. 4). In this case, in order to simplify the analysis,
we focused on 9 lipid classes, including representativemembers of
NLs (CHOL), SLs (CER, SM, dhSM, hexCER, and lacCER), and
GPLs (PC, PE, and PS). These lipid classes included important
membrane components, some of which had been previously as-
sociated with different features of virus infection (8–10, 37, 38).
Relative to infected cells not treated with the drug, a significant
reduction in the content of CHOL, CER, hexCER, PC, PE, and PS
was observed in infected cells treated with TOFA (Fig. 4A). Over-
all, these results supported the idea that, as observed in uninfected
cells (Fig. 1), TOFA inhibited lipid synthesis in WNV-infected
cells. Among the 9 lipid classes compared, a total of 119 different
molecular species could be identified and analyzed (Fig. 4B to F).
FIG 4 Reduction of cellular lipid content in WNV-infected cells treated with TOFA. (A) Relative amounts of different lipid classes in Vero cells infected with
WNV (MOI of 50 PFU/cell) and treated with 10 g/ml TOFA or not (DMSO), determined by mass spectrometry at 24 h p.i. The experiments were performed
in serum-free medium. Statistically significant differences are indicated: *, P 0.05; **, P 0.005. (B to F) Relative amounts of different lipid molecular species
(SLs [B], CHOL [C], PC [D], PE [E], and PS [F]) in cells infected with WNV and treated with TOFA as in panel A. Black bars denote molecular species
significantly altered (P 0.05) relative to untreated infected cells. Gray bars denotemolecular species not significantly changed relative to untreated infected cells.
Bars corresponding to untreated infected cells have been omitted from the figure for clarity. Dashed lines, mean value for each lipid in untreated infected cells.
Data are presented as means SDs (three replicates).
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A significant reduction of 59 molecular species was noted in in-
fected cells treated with TOFA (49.6% of species analyzed), 48 of
which (81%of species analyzed) were also significantly reduced in
uninfected cells treated with TOFA (Fig. 1). These findings indi-
cated that the lipid changes induced by TOFAwere similar in both
WNV-infected and uninfected cells.
MEDICA16 inhibits the infectionofWNVandUSUV.Treat-
ment of Vero cells with MEDICA 16, an ACC inhibitor different
from TOFA (39), also resulted in a dose-dependent inhibition of
the production of infectiousWNV(Fig. 5A) at concentrations that
did not severely impair the viability of the cells (Fig. 5B). The
quantification of genome-containing particles by quantitative
RT-PCR revealed that MEDICA 16 reduced the release of these
viral particles to the culture medium (Fig. 5C). Remarkably, the
extent of this inhibition was lower than the reduction produced in
virus yield (compare Fig. 5A andC). This could indicate that treat-
ment with MEDICA 16 was inducing the formation of noninfec-
tious genome-containingWNVparticles, a phenomenon that was
not observed in infected cells treated with TOFA, in which the
decrease in the production of infectious particles was similar to
the reduction in the release of genome-containing particles (Fig.
2). Moreover, the concentration of 50 g/ml MEDICA 16 that
inhibited the production of infectious WNV and the release of
genome-containing particles did not inhibit accumulation of cell-
associated viral RNA within infected cells. However, a significant
reduction of viral replication was observed at a higher concentra-
tion of 70 g/ml (Fig. 5D). Nevertheless, MEDICA 16 strongly
inhibited the infection with USUV (Fig. 5E), confirming that this
hypolipidemic agent can also inhibit the multiplication of WNV-
related flaviviruses.
DISCUSSION
Lipids play multifaceted roles during virus infection. In such sce-
narios, the pharmacological manipulation of cellular lipids can
reduce virus infection by different mechanisms. These mecha-
nisms include (i) the impairment of membrane rearrangements
associated with viral replication, (ii) the generation of an unfavor-
ablemetabolic environment for virus replication, or (iii) the alter-
ation of the viral envelope composition and the impairment of
viral particle assembly (8, 17, 18, 31).
Treatment with TOFA reduced the synthesis of multiple cellu-
lar lipids, including those previously described to be involved in
WNV infection, such as GPLs, SLs, and CHOL (8, 10, 15). Our
electron microscopy results showed that TOFA induced a reduc-
tion in the amount of membrane rearrangements associated with
WNV replication. In addition, quantitative RT-PCR analysis in-
dicated that this drug reduced the synthesis of viral RNA, which
was compatible with the reduction of the accumulation of dsRNA
intermediates observed by immunofluorescence in infected cells
treated with TOFA. Taken together, all these results suggest that
the inhibition of lipid synthesis exerted by TOFA could impair the
membrane rearrangements necessary for the replication ofWNV.
This mechanism of action would be similar to that recently re-
ported for hepatitis C virus in cells treated with an inhibitor of the
ACC (34). An additional point to be considered is that although
treatment with TOFA reduced the amount of multiple lipid spe-
cies, it also increased the amount of some lysolipids. Interestingly,
the production of these lysolipids could be related to an activation
of a stress response in TOFA-treated cells (35). The possible con-
FIG 5 MEDICA 16 inhibits WNV and USUV multiplication. (A) Reduction
ofWNV infectious particle production in Vero cells treated withMEDICA 16.
Cells were infectedwithWNV (MOI of 0.5 PFU/cell), and virus yield in culture
supernatant was determined by plaque assay at 24 h p.i. (B) Evaluation of the
toxicity ofMEDICA 16 onVero cells by determination of cellular ATP content
24 h posttreatment. (C)Determination by quantitative RT-PCRof the amount
of genome-containing particles in culture supernatant of Vero cells infected
with WNV (MOI of 0.5 PFU/cell) at 24 h p.i. (D) Amount of cell-associated
viral RNA in cell cultures infected with WNV (MOI of 0.5 PFU/cell) and
treated with MEDICA 16 determined by quantitative RT-PCR at 24 h p.i. (E)
Inhibition of USUV infection in Vero cells using MEDICA 16. Vero cells were
infected with USUV (MOI of 0.5 PFU/cell) and treated withMEDICA 16, and
virus yield was determined by plaque assay at 24 h p.i. Data are presented as
means  SDs (three replicates). Statistically significant differences are indi-
cated: *, P 0.05; **, P 0.005.
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tributions of this stress to the antiviral effect of TOFA still remain
to be evaluated.
In the case of the other ACC inhibitor tested, MEDICA 16, the
inhibition exerted by the lowest concentration of this drug assayed
(50 g/ml) seemed to rely mainly on a reduction of infectious
virions rather than on RNA synthesis inhibition, although at a
high concentration (70 g/ml) this drug also inhibited RNA rep-
lication. Blockage of infectious virus production has been de-
scribed for other viruses treated with drugs affecting lipid metab-
olism (31, 40). In this regard, it should be considered that
replication and assembly of viral particles are coupled processes in
flaviviruses (5). This may explain our results showing that the
alteration of lipidmetabolism could affect both processes. In con-
trast to what was described for other members of the Flaviviridae
family (41), there is no evidence, to our knowledge, of palmitoyl-
ation ofWNV proteins. Thus, palmitoylation does not seem to be
an antiviral target of action for ACC inhibitors inWNV infection.
Although the strategy of manipulating a major cellular meta-
bolic pathway such as lipid biosynthesis could induce multiple
side effects in vivo, it has to be considered that current antivirals
target other major biosynthetic pathways, such as nucleotide bio-
synthesis (for a discussion, see reference 18). Indeed, the clinical
value of lipid-lowering agents such as the statins, which are cho-
lesterol synthesis inhibitors broadly used against cardiovascular
diseases, supports the feasibility of therapeutic interventions tar-
geting the lipid metabolism (42). Consistently, hypolipidemic
drugs targeting the ACC are being evaluated for the treatment of
multiple human disorders from certain cancers to obesity and
diabetes (20, 21) and even viral infections (18, 34, 43). In addition,
the results obtained with hypolipidemic agents (i.e., nordihydro-
guaiaretic acid) that target cellular factors other than ACC also
support the feasibility of lipid-based antiviral approaches (17, 44).
In this context, the potential of ACC inhibitors reported here to
impair the replication of different flaviviruses, such as WNV and
USUV, could contribute to the development of broad-spectrum
antiflaviviral drugs.
In this work, we have provided further evidence supporting the
idea that pharmacological manipulation of the lipid biosynthetic
route can impair flavivirus infection. Specifically, we have identi-
fied the ACC as a druggable target to be considered for antiviral
development against WNV and related flaviviruses.
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